1. Home
  2. IDE vs MDWD Comparison

IDE vs MDWD Comparison

Compare IDE & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IDE
  • MDWD
  • Stock Information
  • Founded
  • IDE 2010
  • MDWD 2000
  • Country
  • IDE United States
  • MDWD Israel
  • Employees
  • IDE N/A
  • MDWD N/A
  • Industry
  • IDE Finance/Investors Services
  • MDWD Medicinal Chemicals and Botanical Products
  • Sector
  • IDE Finance
  • MDWD Health Care
  • Exchange
  • IDE Nasdaq
  • MDWD Nasdaq
  • Market Cap
  • IDE 186.0M
  • MDWD 195.2M
  • IPO Year
  • IDE N/A
  • MDWD 2014
  • Fundamental
  • Price
  • IDE $12.31
  • MDWD $18.33
  • Analyst Decision
  • IDE
  • MDWD Strong Buy
  • Analyst Count
  • IDE 0
  • MDWD 2
  • Target Price
  • IDE N/A
  • MDWD $35.00
  • AVG Volume (30 Days)
  • IDE 33.5K
  • MDWD 69.9K
  • Earning Date
  • IDE 01-01-0001
  • MDWD 11-25-2025
  • Dividend Yield
  • IDE 8.83%
  • MDWD N/A
  • EPS Growth
  • IDE N/A
  • MDWD N/A
  • EPS
  • IDE N/A
  • MDWD N/A
  • Revenue
  • IDE N/A
  • MDWD $19,858,000.00
  • Revenue This Year
  • IDE N/A
  • MDWD $21.39
  • Revenue Next Year
  • IDE N/A
  • MDWD $23.01
  • P/E Ratio
  • IDE N/A
  • MDWD N/A
  • Revenue Growth
  • IDE N/A
  • MDWD N/A
  • 52 Week Low
  • IDE $8.61
  • MDWD $14.14
  • 52 Week High
  • IDE $10.46
  • MDWD $22.51
  • Technical
  • Relative Strength Index (RSI)
  • IDE 54.35
  • MDWD 50.45
  • Support Level
  • IDE $12.18
  • MDWD $17.97
  • Resistance Level
  • IDE $12.35
  • MDWD $18.79
  • Average True Range (ATR)
  • IDE 0.15
  • MDWD 0.72
  • MACD
  • IDE 0.02
  • MDWD -0.08
  • Stochastic Oscillator
  • IDE 79.63
  • MDWD 18.27

About IDE Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: